AUTHOR=Wei Jinjing , Wang Ruxin , Ye Haowen , Wang Ying , Wang Lihong , Zhang Xiaofang 

TITLE=Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis

JOURNAL=Frontiers in Endocrinology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.910256

DOI=10.3389/fendo.2022.910256

ISSN=1664-2392

ABSTRACT=<sec><title>Purpose</title><p>An update of a systematic review and meta-analysis of the risk of arrhythmias and their subtypes in type 2 diabetic patients receiving glucagon-like peptide 1 receptor agonist (GLP-1RA) medication according to data from the Cardiovascular Outcome Trial(CVOT).</p></sec><sec><title>Methods</title><p>Randomized controlled trials (RCT) on GLP-1RA therapy and cardiovascular outcomes in type 2 diabetes mellitus patients published in full-text journal databases such as MEDLINE (via PubMed), Embase, Clinical Trials.gov, and the Cochrane Library from establishment to March 1, 2022 were searched. We assessed the quality of individual studies by the Cochrane risk-of-bias algorithm. RevMan 5.4.1 software was use for calculating meta-analysis.</p></sec><sec><title>Results</title><p>A total of 60,081 randomized participants were included in the data of these 8 GLP-1RA cardiovascular outcomes trials. Pooled analysis reported no significant effect on total arrhythmia [RR=0.96, 95% CI (0.96, 1.05), <italic>p</italic> =0.36], and its subtypes such as atrial fibrillation [RR=0.96, 95% CI (0.86, 1.07), <italic>p</italic> =0.43], atrial flutter [RR= 0.82, 95% CI (0.57, 1.19), <italic>p</italic> =0.30], atrial tachycardia [RR=0.64, 95% CI (0.20, 2.01), <italic>p</italic> =0.44)], sinoatrial node dysfunction [RR=0.74, 95% CI (0.44, 1.25), <italic>p</italic> =0.26], ventricular preterm systole [RR=1.42, 95% CI (0.62, 3.26), <italic>p</italic> =0.41], second degree AV block [RR=0.96, 95% CI (0.53, 1.72), <italic>p</italic> =0.88], complete AV block [RR=0.75, 95% CI (0.49, 1.17), <italic>p</italic> =0.21], ventricular fibrillation [RR=1.00, 95% CI (0.50, 2.02), <italic>p</italic> =1.00], ventricular tachycardia [RR=1.37, 95% CI (0.91, 2.08), <italic>p</italic> =0.13] from treatment with GLP-1RA versus placebo. However, the risk of hypoglycemia was reduced by about 30% [RR=0.70, 95% CI (0.57, 0.87), <italic>p</italic>=0.001] and the risk of pneumonia by about 25% [RR=0.85, 95% CI (0.75, 0.97), <italic>p</italic>=0.01], both statistically significant differences.</p></sec><sec><title>Conclusion</title><p>In type 2 diabetic patients, treatment with GLP-1RA has no significant effect on the risk of major arrhythmias but significantly reduces the risk of hypoglycemia and pneumonia.</p></sec>